How to use Technologies searched

A search for a company looking for a cancer, preclinical stage, synthetic opportunity would use the selection "Biomedicine, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform technology' in 'Sector' will identify all kinds of searches for technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each search profile gives the name or a short description of the company behind the search, and a link allowing to contact your potential licensee.

Registered users can create non-public notifications profiles which will inform them about new Technologies Searched entries fitting their expertise as specified. In addition these profiles allow them to filter the available information more comfortably.


Shire is looking for opportunities in Central Nervous System (CNS) / Neuropsychiatry, Gastrointestinal, Orphan genetic diseases, Allergy and Hematology

Organization name

Shire Pharmaceuticals Group, Plc


About Shire

Shire Pharmaceuticals is a rapidly growing, international specialty biopharmaceutical company. Shire’s development focus is in central nervous system disorders, gastro-intestinal, regenerative medicine, human genetic therapies and orphan diseases. Shire has completed nine mergers and acquisitions in eleven years. In-licensing and product acquisitions are a priority at Shire.

The SIG is Shire’s corporate venture fund, tasked with identifying and investing in external innovation that may bring new products to Shire’s pipeline and which support Shire’s overall mission to enable people with life-altering conditions to lead better lives.

Further to that mission, Shire is focused on delivering novel, cost-effective therapies to patients with symptomatic diseases and significant unmet medical need.

Accordingly, the SIG seeks to invest across a broad range of therapeutic areas of interest including, but not limited to, the following:

  • Central Nervous System (CNS) / Neuropsychiatry
  • Gastrointestinal
  • Orphan genetic diseases
  • Allergy
  • Hematology

The SIG also pursues investments in “white space” technology – areas outside the traditional bounds of its existing businesses.

Depending upon the indication, collaborations may be formed at various stages of the development process.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries